The DOI matches its Crossref record; 33 of the 38 references it cites were found in a registry or an index.
Immunogenicity of combined hepatitis A and B vaccine in elderly persons
Abstract
More and more elderly people travel to areas where hepatitis A and B are endemic. Their immune system is less effective than in young persons. Therefore, it has to be insured that these travelers have protective immunity after vaccination. In a retrospective study we measured anti hepatitis virus (anti-HAV) and anti-HBs in elderly persons (N = 104, mean age 54 years) after combined hepatitis A/B vaccination under every-day conditions. After complete vaccination only 36 (34.6%) had antibodies against both viruses. Only 23 (29%) of 80 vaccinees older than 40 years were protected against hepatitis B and 52 (65%) against hepatitis A. The response to the vaccination decreased with increasing age. Vaccination against hepatitis B-but not against hepatitis A-was also influenced by the presence of chronic disease. After one booster 87% of the anti-HAV negative vaccinees developed protective anti-HAV antibodies. Anti-HBs can be expected in about 50% of the HBV negative vaccinees with every single booster. These results indicate that combined hepatitis A/B vaccination is not very effective in elderly persons. After complete vaccination their anti-HAV and anti-HBs antibodies have to be controlled to insure protection. In case of vaccination-failure boosters are very effective.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The immune system changes with age in nearly every aspect, generally resulting in a decline in pathogen immunity with increased age.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [4]
In the citing paper
“ageing is associated with high morbidity and mortality rates for various infections and significant reductions in vaccine efficacy1-6”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [4]
Citations
Cites
Wood, R. C. (1993) · JAMA · doi:10.1001/jama.1993.03510240047030 · Cited by 286
Goldstein, S. T., Alter, M. J., Williams, I. T., Moyer, L. A., Judson, F. N., Mottram, K., Fleenor, M. E., Ryder, P. L., & Margolis, H. S. (2002) · The Journal of Infectious Diseases · doi:10.1086/339192 · Cited by 281
Federal Statistical Office, Germany
(2003) · Choice Reviews Online · doi:10.5860/choice.41-1312 · Cited by 196
The first combined vaccine against hepatitis A and B: an overview
Thoelen, S., Damme, P. V., Leentvaar-Kuypers, A., Leroux-Roels, G. G., Bruguera, M., Frei, P. C., Bakasénas, V., & Safary, A. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00421-6 · Cited by 121
Joines, R. W., Blatter, M. M., Abraham, B., Xie, F., Clercq, N. D., Baine, Y., Reisinger, K. S., Kuhnen, A. E., & Parenti, D. L. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00240-7 · Cited by 110
Rendi‐Wagner, P., Kundi, M., Stemberger, H., Wiedermann, G., Holzmann, H., Hofer, M., Wiesinger, K., & Kollaritsch, H. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00410-2 · Cited by 109
Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen
McMahon, B. J., Parkinson, A. J., Helminiak, C., Wainwright, R. B., BULKOW, L. R., Kellerman-Douglas, A., Schoenberg, S., & Ritter, D. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90851-o · Cited by 97
Hepatitis-B Vaccination in the Elderly
Denis, F., Mounier, M., Hessel, L., Michel, J., Gualde, N., Dubois, F., Barin, F., & Goudeau, A. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/149.6.1019 · Cited by 95
Thierfelder, W., Hellenbrand, W., Meisel, H., Schreier, E., & Dortschy, R. (2001) · European Journal of Epidemiology · doi:10.1023/a:1013792013184 · Cited by 83
Reuman, P. D., Kubilis, P. S., Hurni, W. M., Brown, L., & Nalin, D. R. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00310-6 · Cited by 78
Research works printed but not linked: 3
- FDA approval for a combined hepatitis A and B vaccine. MMWR Morb Mortal Wkly Rep 2001;50:806–7.
- Keystone J, Parsons J, Anstey R. Reactogenicity and immunogenicity of a combined vaccine against hepatitis A and B in older adults. In: Proceedings of the Ninth Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, 21–25 April 1996, C324.
- Hofmann, 1997, Zur Effizienz der Hepatitis B-Schutzimpfung, Gesundheitswesen, 59, 527
Cited by
Sorted by citations
Factors That Influence the Immune Response to Vaccination
Zimmermann, P., & Curtis, N. C. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00084-18 · Cited by 970
The Xs and Y of immune responses to viral vaccines
Klein, S. L., Jedlicka, A., & Pekosz, A. S. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70049-9 · Cited by 813
How sex and age affect immune responses, susceptibility to infections, and response to vaccination
Giefing, C., Berger, P., Lepperdinger, G., & Grubeck‐Loebenstein, B. (2015) · Aging Cell · doi:10.1111/acel.12326 · Cited by 796
Biology of Immune Responses to Vaccines in Elderly Persons
Weinberger, B., Herndler‐Brandstetter, D., Schwanninger, A., Weiskopf, D., & Grubeck‐Loebenstein, B. (2008) · Clinical Infectious Diseases · doi:10.1086/529197 · Cited by 392
SARS-CoV-2, COVID-19 and the aging immune system
Bartleson, J. M., Radenkovic, D., Covarrubias, A. J., Furman, D., Winer, D. A., & Verdin, E. (2021) · Nature Aging · doi:10.1038/s43587-021-00114-7 · Cited by 359
Metadata
- Authors
- Wolters, B., Junge, U., Dziuba, S., & Roggendorf, M.
- Affiliations
- University of Duisburg-Essen (DE)
- Klinikum Bielefeld (DE)
- Corresponding author
- Roggendorf, Michael
- ORCID
- Roggendorf, Michael
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2003-09
- Volume
- 21
- Issue
- 25-26
- Pages
- 3623-3628
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W1980161689
- Cited by
- 116
- References
- 38
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 10 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 3 · 2013: 5 · 2012: 10
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Vaccine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Hepatology › Hepatitis Viruses Studies and Epidemiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
- Keywords
- immunogenicity, older adults, anti-HAV antibodies, anti-HBs antibodies, vaccine response, booster vaccination, vaccine failure, chronic disease, travel vaccination, age-related immune decline
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Health Status, Hepatitis B Surface Antigens, Humans, Immunization Schedule, Immunization, Secondary, Male, Middle Aged, Retrospective Studies, Hepatitis B Vaccines, Vaccines, Combined, Hepatitis A Vaccines, Hepatitis A Antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
